Literature DB >> 19781955

Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.

Alexandra Schramm1, Isabelle Opitz, Svenja Thies, Burkhardt Seifert, Holger Moch, Walter Weder, Alex Soltermann.   

Abstract

BACKGROUND: Epithelial-to-mesenchymal transition (EMT) is a morphologic transdifferentiation of carcinomas, conferring increased tumour invasiveness, but may also be applied to the epithelioid versus sarcomatoid histotype of malignant pleural mesothelioma (MPM). Herein, we correlated proteins of a putative MPM-EMT axis, including periostin, epidermal growth factor receptor (EGFR), integrin beta1, phosphatase and tensin homologue (PTEN), integrin-linked kinase (ILK), p21 and p27, with clinico-pathologic parameters, in particular overall survival (OS). PATIENTS AND METHODS: A retrospective cohort of 352 mostly untreated patients with MPM was investigated by immunohistochemistry of a tissue microarray. Protein expression intensities were semi-quantitatively scored from 0 to 3 in their respective compartments, including peritumoural stroma as well as tumour cell plasma membrane, cytoplasm or nucleus. Data were correlated with histotype and survival outcome.
RESULTS: A total of 32% of the tumours were diagnosed as epithelioid, 13% as sarcomatoid and 55% as biphasic histotype. High expression of membranous EGFR and integrin beta1 as well as nuclear p27 correlated with the epithelioid and high expression of cytoplasmic tumoural and stromal periostin with the sarcomatoid histotype. The median survival time of the 128 patients with complete follow-up data was 11.7 months. Univariate survival analysis revealed age, epithelioid histotype and any therapy as prognosticators for better OS. High expression of cytoplasmic PTEN or ILK as well as high expression of nuclear p21 or p27 correlated with increased, whereas high expression of cytoplasmic periostin with decreased OS (all p values <0.05). Multivariate Cox regression revealed any treatment, low cytoplasmic periostin and high cytoplasmic PTEN as independent prognosticators for better OS.
CONCLUSION: Activation of periostin-triggered EMT is associated with the sarcomatoid histotype and has an impact on shorter survival of MPM patients. Finally, only the high expression of PTEN and the low expression of cytosolic periostin could be shown to be independent prognostic factors for longer OS. Copyright (c) 2009. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19781955     DOI: 10.1016/j.ejcts.2009.08.027

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  34 in total

1.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 2.  MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets.

Authors:  Glen Reid
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 3.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

4.  Relevance of periostin splice variants in renal cell carcinoma.

Authors:  Laura Morra; Markus Rechsteiner; Silvia Casagrande; Van Duc Luu; Roger Santimaria; Pierre A Diener; Tullio Sulser; Glen Kristiansen; Peter Schraml; Holger Moch; Alex Soltermann
Journal:  Am J Pathol       Date:  2011-07-18       Impact factor: 4.307

5.  Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.

Authors:  Mihoko Horio; Mitsuo Sato; Yoshihiro Takeyama; Momen Elshazley; Ryo Yamashita; Tetsunari Hase; Kenya Yoshida; Noriyasu Usami; Kohei Yokoi; Yoshitaka Sekido; Masashi Kondo; Shinya Toyokuni; Adi F Gazdar; John D Minna; Yoshinori Hasegawa
Journal:  Ann Surg Oncol       Date:  2011-11-16       Impact factor: 5.344

6.  hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.

Authors:  Harvey I Pass; Chandra Goparaju; Sergey Ivanov; Jessica Donington; Michele Carbone; Moshe Hoshen; Dalia Cohen; Ayelet Chajut; Shai Rosenwald; Harel Dan; Sima Benjamin; Ranit Aharonov
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

7.  MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.

Authors:  Michaela B Kirschner; Yuen Yee Cheng; Nicola J Armstrong; Ruby C Y Lin; Steven C Kao; Anthony Linton; Sonja Klebe; Brian C McCaughan; Nico van Zandwijk; Glen Reid
Journal:  Mol Oncol       Date:  2014-12-02       Impact factor: 6.603

8.  Exosomes from asbestos-exposed cells modulate gene expression in mesothelial cells.

Authors:  Phillip Munson; Ying-Wai Lam; Julie Dragon; Maximilian MacPherson; Arti Shukla
Journal:  FASEB J       Date:  2018-03-19       Impact factor: 5.191

Review 9.  Pleural mesothelial cells in pleural and lung diseases.

Authors:  Hitesh Batra; Veena B Antony
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

10.  Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.

Authors:  M Cioce; F Ganci; V Canu; A Sacconi; F Mori; C Canino; E Korita; B Casini; G Alessandrini; A Cambria; M A Carosi; R Blandino; V Panebianco; F Facciolo; P Visca; S Volinia; P Muti; S Strano; C M Croce; H I Pass; G Blandino
Journal:  Oncogene       Date:  2013-11-18       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.